Clinical trials: Hair Diseases
Alopecia
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of 0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia types III vertex, IV and V per the…
- Trial name
- NCT01831791
- Testing
- Dutasteride 0.5 mg
- Where
- 5 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Hypotrichosis
Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin
This one-year study evaluates the long-term safety and effectiveness of bimatoprost solution application to the eyelid margin (where the eyelashes meet the skin) to treat hypotrichosis of the eyelashes (inadequate or not enough…
- Trial name
- NCT00907426
- Testing
- Bimatoprost 0.03% solution, Vehicle solution
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 368 people
- Sponsor
- Allergan
Alopecia Areata
A Study of KL130008 in Adults With Severe Alopecia Areata
The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata
- Trial name
- NCT05496426
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Alopecia Areata
LEO 124249 Ointment in the Treatment of Alopecia Areata
This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.
- Trial name
- NCT02561585
- Testing
- LEO 124249, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Androgenetic Alopecia, Alopecia
THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microenvironment Modulation
To evaluate the safety and clinical performance of THERAVEX® REGENERA Tissue Care Plus as an adjunctive regenerative support therapy in patients undergoing hair restoration procedures and regenerative scalp treatment protocols.
- Conditions
- Androgenetic Alopecia, Alopecia, Hair Loss, Non-scarring Alopecia
- Trial name
- NCT07615608
- Testing
- Standard Hair Restoration Care
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biointelligent Technology Systems SL
Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at…
- Trial name
- NCT05368103
- Testing
- Daxdilimab
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Amgen
Female Pattern Hair Loss, Androgenetic Alopecia (AGA)
A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss
Pantovigar - a high effective product designed primarily for the treatment of diffuse hair loss in women as well as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of…
- Conditions
- Female Pattern Hair Loss, Androgenetic Alopecia (AGA), Ludwig Type 1, Ludwig Type 2
- Trial name
- NCT01900041
- Testing
- Pantovigar, Minoxidil 2% only
- Where
- 2 sites in Russia
- Volunteers
- 74 people
- Sponsor
- Merz Pharmaceuticals GmbH
Folliculitis
Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated
The objective of this trial is to evaluate the comparative efficacy of the combination of Clotrimazole + Gentamicin + Beclomethasone in study subjects with a condition of contaminated dermatosis showing bilateral symmetrical…
- Trial name
- acne (NCT01244256)
- Testing
- Clotrimazole + Gentamicin + Beclomethasone, Clotrimazole + Gentamicin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Azidus Brasil
Chemotherapy-Induced Alopecia
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
The goal of this clinical trial is to learn if Compound 31543 (topical calcitriol) for treatment of hair-loss in patients with a diagnosis of breast cancer, gynecologic cancer or sarcomas receiving a taxane-based chemotherapy is…
- Trial name
- NCT01588522
- Testing
- Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- BPGbio
Prostate Cancer, Hirsutism
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
The purpose of this study is to demonstrate the relative bioavailability of Bicalutamide 50 mg tablet and Casodex following a 50 mg dose in healthy subjects under fed conditions.
- Trial name
- NCT00960310
- Testing
- Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA), Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Telogen Effluvium
BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women.
- Trial name
- NCT04880889
- Testing
- BL 3000, Reference Pantogar
- Volunteers
- 326 people
- Sponsor
- Biolab Sanus Farmaceutica
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Breast Neoplasms
Use of Hair to Diagnose Breast Cancer
Study FT3.6k-2006 is a single centre (the Mater Hospital, Sydney), blinded trial of a diagnostic test for breast cancer, with outcomes compared to the gold standard of screening mammogram followed by biopsy where required.
- Trial name
- NCT00419679
- Testing
- x-ray diffraction of human hair
- Where
- Australia
- Volunteers
- 3,600 people
- Sponsor
- Fermiscan Ltd
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
- Trial name
- AZURE (NCT05205070)
- Testing
- Rosnilimab
- Where
- 16 sites in United States
- Volunteers
- 45 people
- Sponsor
- AnaptysBio, Inc.
Androgenic Alopecia
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia.
- Trial name
- NCT06112782
- Testing
- Keravive by Hydrafacial Treatments
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Beauty Health
Androgenetic Alopecia
Photosensitization Study in Androgenetic Alopecia
This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)
- Trial name
- NCT02791243
- Testing
- Finasteride 0.25%, Negative Control
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Polichem S.A.
Alopecia Areata
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia…
- Trial name
- NCT07762443
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Males and Females
The purpose of this study is to evaluate the efficacy of Low Level Laser and Light Therapy system configured in a novel product called the TopHat 655 system, for promoting hair growth in males and females diagnosed with…
- Trial name
- LLLT (NCT01437163)
- Testing
- TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Apira Science, Inc.
Severe Alopecia Areata
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.
- Trial name
- B7981028 (NCT07029828)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 67 sites in United States, China and 7 more
- Volunteers
- 140 people
- Sponsor
- Pfizer